0000000000799952

AUTHOR

Roberto Bergamaschi

showing 17 related works from this author

Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.

2022

Background: Definitions for reliable identification of transition from relapsing-remitting multiple sclerosis (MS) to secondary progressive (SP)MS in clinical cohorts are not available. Objectives: To compare diagnostic performances of two different data-driven SPMS definitions. Methods: Data-driven SPMS definitions based on a version of Lorscheider’s algorithm (DDA) and on the EXPAND trial inclusion criteria were compared, using the neurologist’s definition (ND) as gold standard, in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), Akaike information criterion (AIC) and area under the curve (AUC). Results: A cohort of 10,240 MS patients wi…

Multiple SclerosisMultiple Sclerosis Chronic ProgressiveMultiple sclerosisMultiple Sclerosis Relapsing-RemittingNeurologybig dataArea Under Curvedata-driven algorithmdisease registrysecondary progressiveHumansSettore MED/26 - NeurologiaNeurology (clinical)prognosisMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Italian version of the Chicago multiscale depression inventory: translation, adaptation and testing in people with multiple sclerosis.

2004

Depression is the commonest psychiatric disturbance in people with multiple sclerosis (MS), with prevalence higher than in the general population and other chronic diseases. However, accurate assessment of depressive symptoms can be biased by somatic symptoms which are part of both MS and depression. We translated and adapted into Italian the Chicago multiscale depression inventory (CMDI) and assessed its acceptability, internal consistency and test-retest reliability in 213 MS outpatients and 213 individually matched healthy controls. The questionnaire was also tested in 32 people with major depression. Acceptability, internal consistency, and test-retest reliability were good overall. We …

AdultMalemedicine.medical_specialtyMultiple SclerosisPsychometricsAdolescentPersonality InventoryPsychometricsMultiple sclerosis Depression Outcome measures MoodeducationPopulationDermatologySurveys and QuestionnairesOutcome Assessment Health CaremedicineHumanseducationPsychiatryDepression (differential diagnoses)Psychiatric Status Rating Scaleseducation.field_of_studyDepressionMultiple sclerosisCase-control studyAge FactorsReproducibility of ResultsGeneral MedicineOdds ratioMiddle Agedmedicine.diseasePsychiatry and Mental healthMoodItalyEvaluation Studies as TopicCase-Control StudiesFemaleNeurology (clinical)Personality Assessment InventoryPsychologyClinical psychologyNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct

The Effects of Transcutaneous Spinal Direct Current Stimulation on Neuropathic Pain in Multiple Sclerosis: Clinical and Neurophysiological Assessment

2019

Background: Central neuropathic pain represents one of the most common symptoms in multiple sclerosis (MS) and it seriously affects quality of life. Spinal mechanisms may contribute to the pathogenesis of neuropathic pain in MS. Converging evidence from animal models and neurophysiological and clinical studies in humans suggests a potential effect of transcranial direct current stimulation (tc-DCS) on neuropathic pain. Spinal application of DCS, i.e., transcutaneous spinal DCS (ts-DCS), may modulate nociception through inhibition of spinal reflexes. Therefore, ts-DCS could represents an effective, safe and well-tolerated treatment for neuropathic pain in MS, a largely unexplored topic. This…

transcutaneous spinal direct current stimulation (ts-DCS)nociceptive withdrawal reflexmedicine.medical_treatmentnon-invasiveWithdrawal reflexmultiple sclerosis050105 experimental psychologylcsh:RC321-57103 medical and health sciencesBehavioral Neuroscience0302 clinical medicinemedicine0501 psychology and cognitive sciencesSpasticitylcsh:Neurosciences. Biological psychiatry. NeuropsychiatryBiological PsychiatryOriginal Researchneuropathic painTranscranial direct-current stimulationbusiness.industryMultiple sclerosis05 social sciencesmedicine.diseaseNeuromodulation (medicine)Psychiatry and Mental healthNeuropsychology and Physiological PsychologyNociceptionNeurologyAnesthesianeuromodulationNeuropathic painmultiple sclerosis; neuromodulation; neuropathic pain; nociceptive withdrawal reflex; non-invasive; transcutaneous spinal direct current stimulation (ts-DCS)Reflexmedicine.symptombusiness030217 neurology & neurosurgeryNeuroscienceFrontiers in Human Neuroscience
researchProduct

Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study

2022

Portaccio et al. report that in early relapsing-onset multiple sclerosis, progression independent of relapse activity is an important contributor to disability accumulation. Insidious progression occurs even in the earliest disease phases, suggesting that inflammation and degeneration may represent a single disease continuum.Disability accrual in multiple sclerosis may occur as relapse-associated worsening or progression independent of relapse activity. The role of progression independent of relapse activity in early multiple sclerosis is yet to be established. The objective of this multicentre, observational, retrospective cohort study was to investigate the contribution of relapse-associa…

Multiple Sclerosisrelapse-associated worseningprogression independent of relapse activityrelapsing multiple sclerosisCohort StudiesMultiple Sclerosis Relapsing-Remittingrelapse associated worseningRecurrenceChronic DiseaseDisease ProgressionHumansSettore MED/26 - NeurologiaNeurology (clinical)Retrospective Studies
researchProduct

Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.

2021

Objective: To identify baseline factors associated with disease activity in patients with relapsing–remitting multiple sclerosis (RRMS) under teriflunomide treatment. Methods: This was an independent, multi-centre, retrospective post-marketing study. We analysed data of 1,507 patients who started teriflunomide since October 2014 and were regularly followed in 28 Centres in Italy. We reported the proportions of patients who discontinued treatment (after excluding 32 lost to follow-up) and who experienced clinical disease activity, i.e., relapse(s) and/or confirmed disability worsening, as assessed by the Expanded Disability Status Scale (EDSS). Decision tree-based analysis was performed to i…

medicine.medical_specialtyNeurologyMultiple SclerosisToluidinesHydroxybutyratesOral drugsDiseaseRelapsing-RemittingSettore MED/26Pregnancy planning03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicineTeriflunomideTeriflunomideNitrilesmedicineHumans030212 general & internal medicineAdverse effectRetrospective StudiesExpanded Disability Status Scalebusiness.industryMultiple sclerosismedicine.diseaseSettore MED/26 - NEUROLOGIANeurologychemistryTolerabilityItalyMultiple sclerosis; Oral drugs; Teriflunomide; Crotonates; Humans; Hydroxybutyrates; Italy; Nitriles; Retrospective Studies; Toluidines; Multiple Sclerosis; Multiple Sclerosis Relapsing-RemittingCrotonatesNeurology (clinical)business030217 neurology & neurosurgeryJournal of neurology
researchProduct

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.

2011

Multiple sclerosis is a common disease of the central nervous system in which the interplay between inflammatory and neurodegenerative processes typically results in intermittent neurological disturbance followed by progressive accumulation of disability. Epidemiological studies have shown that genetic factors are primarily responsible for the substantially increased frequency of the disease seen in the relatives of affected individuals, and systematic attempts to identify linkage in multiplex families have confirmed that variation within the major histocompatibility complex (MHC) exerts the greatest individual effect on risk. Modestly powered genome-wide association studies (GWAS) have ena…

Immunity Cellular/geneticsCellular immunityMultiple SclerosisGenome-wide association studyCLEC16ABiologyPolymorphism Single NucleotideCell Differentiation/immunologyEurope/ethnologyMajor Histocompatibility Complex/geneticsMajor Histocompatibility Complex03 medical and health sciences0302 clinical medicinemedicineGenetic predispositionHumansGenetic Predisposition to DiseaseHLA-A Antigens/geneticsAlleles030304 developmental biologyGenetic associationGenetics0303 health sciencesImmunity CellularMultidisciplinaryHLA-A AntigensGenome HumanMultiple sclerosisGenetic Predisposition to Disease/geneticsHLA-DR Antigens/geneticsLymphocyte differentiationCell DifferentiationHLA-DR AntigensT-Lymphocytes Helper-InducerRC346medicine.diseasePolymorphism Single Nucleotide/geneticsGenetic architecture3. Good healthEuropeSample SizeImmunologyGenome Human/geneticsMultiple Sclerosis/genetics030217 neurology & neurosurgeryT-Lymphocytes Helper-Inducer/cytologyGenome-Wide Association StudyHLA-DRB1 Chains
researchProduct

Electrophysiological patterns of oropharyngeal swallowing in multiple sclerosis.

2012

Abstract Objective We performed an electrophysiological study of swallowing (EPSS) in multiple sclerosis (MS) to describe oropharyngeal swallowing abnormalities and to analyze their correlations with dysphagia and with overall neurological impairment. Methods Neurological examinations were quantified using the Kurtzke Functional Systems and the Expanded Disability Status Scale (EDSS). Dysphagia was evaluated using the Dysphagia in Multiple Sclerosis (DYMUS) questionnaire, while fiberoptic endoscopic evaluation of swallowing (FEES) was used to establish the degree of aspiration and penetration, graded using the penetration–aspiration scale (PAS). The EPSS measured the duration of suprahyoid/…

AdultMalemedicine.medical_specialtyMultiple SclerosisOropharynxElectromyographyBladder Sphincter DysfunctionDysphagia swallowing electromiography multiple sclerosisSwallowingPhysiology (medical)otorhinolaryngologic diseasesmedicineHumansAgedExpanded Disability Status Scalemedicine.diagnostic_testbusiness.industryElectromyographyMultiple sclerosisMiddle Agedmedicine.diseaseDysphagiaSensory SystemsPathophysiologySurgeryDeglutitionNeurologyAnesthesiaFemaleNeurology (clinical)medicine.symptomAbnormalitybusinessDeglutition DisordersClinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
researchProduct

Prognostic indicators in pediatric clinically isolated syndrome

2017

Objective To assess prognostic factors for a second clinical attack and a first disability-worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of multiple sclerosis (MS) patients. Methods A cohort of 770 pCIS patients was followed up for at least 10 years. Cox proportional hazard models and Recursive Partitioning and Amalgamation (RECPAM) tree-regression were used to analyze data. Results In pCIS, female sex and a multifocal onset were risk factors for a second clinical attack (hazard ratio [HR], 95% confidence interval [CI] = 1.28, 1.06–1.55; 1.42, 1.10–1.84, respectively), whereas disease-modifying drug (DMD) exposure reduced this risk (HR, 95% CI = 0.75, 0.60–0.95…

0301 basic medicinemedicine.medical_specialtyeducation.field_of_studyClinically isolated syndromeExpanded Disability Status Scalebusiness.industryProportional hazards modelHazard ratioPopulationRetrospective cohort studySurgery03 medical and health sciences030104 developmental biology0302 clinical medicineNeurologyInternal medicineMedicineNeurology (clinical)Age of onsetRisk factorbusinesseducation030217 neurology & neurosurgeryAnnals of Neurology
researchProduct

Real-life impact of early interferonβ therapy in relapsing multiple sclerosis

2009

Objective: Recent findings support greater efficacy of early vs. delayed interferon beta (IFN) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS). We aimed to evaluate the effectiveness of early IFN treatment in definite relapsing-remitting MS (RRMS) and to assess the optimal time to initiate IFN treatment with regard to the greatest benefits on disability progression. Methods: A cohort of 2,570 IFN-treated RRMS patients was prospectively followed for up to 7 years in 15 Italian MS Centers. A Cox proportional hazards regression model adjusted for propensity score (PS) quintiles was used to assess differences between groups of patients with early vs. dela…

medicine.medical_specialtyExpanded Disability Status Scalebusiness.industryMultiple sclerosisHazard ratiomedicine.diseaseSurgeryCentral nervous system diseaseNeurologyInternal medicinePropensity score matchingCohortmedicineObservational studyNeurology (clinical)Unmeasured confoundingbusinessAnnals of Neurology
researchProduct

Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis

2020

Abstract An ever-expanding number of disease-modifying drugs for multiple sclerosis have become available in recent years, after demonstrating efficacy in clinical trials. In the real-world setting, however, disease-modifying drugs are prescribed in patient populations that differ from those included in pivotal studies, where extreme age patients are usually excluded or under-represented. In this multicentre, observational, retrospective Italian cohort study, we evaluated treatment exposure in three cohorts of patients with relapsing-remitting multiple sclerosis defined by age at onset: paediatric-onset (≤18 years), adult-onset (18–49 years) and late-onset multiple sclerosis (≥50 years). We…

AdultMalemedicine.medical_specialtyneuroinflammationCohort Studies03 medical and health sciences0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicinemedicineHumansDisabled Persons030212 general & internal medicineProspective StudiesRisk factorclinical trials; clinically isolated syndrome; demyelination; multiple sclerosis epidemiology; neuroinflammationRetrospective Studiesclinical trialsClinically isolated syndromeExpanded Disability Status ScaleProportional hazards modelbusiness.industryHazard ratioMiddle AgedItalyAntirheumatic Agentsclinically isolated syndromeCohortDisease Progressionmultiple sclerosis epidemiologySettore MED/26 - NeurologiaFemaleNeurology (clinical)demyelinationAge of onsetbusiness030217 neurology & neurosurgeryCohort studyFollow-Up Studies
researchProduct

Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies

2021

Background and aims: No consensus exists on how aggressively to treat relapsing–remitting multiple sclerosis (RRMS) nor on the timing of the treatment. The objective of this study was to evaluate disability trajectories in RRMS patients treated with an early intensive treatment (EIT) or with a moderate-efficacy treatment followed by escalation to higher-efficacy disease modifying therapy (ESC). Methods: RRMS patients with ⩾5-year follow-up and ⩾3 visits after disease modifying therapy (DMT) start were selected from the Italian MS Registry. EIT group included patients who received as first DMT fingolimod, natalizumab, mitoxantrone, alemtuzumab, ocrelizumab, cladribine. ESC group patients rec…

Pediatricsmedicine.medical_specialtybig data; disability trajectories; disease registry; multiple sclerosis.multiple sclerosis03 medical and health sciences0302 clinical medicineDisease registrybig dataMedicine030212 general & internal medicineRC346-429Original Researchbig data; disability trajectories; disease registry; multiple sclerosisPharmacologybusiness.industryMultiple sclerosisLong term disabilitymedicine.diseaseNeurologydisease registryTreatment strategySettore MED/26 - Neurologiadisability trajectoriesNeurology. Diseases of the nervous systemNeurology (clinical)business030217 neurology & neurosurgeryTherapeutic Advances in Neurological Disorders
researchProduct

Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors

2021

Background: No uniform criteria for a sensitive identification of the transition from relapsing–remitting multiple sclerosis (MS) to secondary-progressive multiple sclerosis (SPMS) are available. Objective: To compare risk factors of SPMS using two definitions: one based on the neurologist judgment (ND) and an objective data-driven algorithm (DDA). Methods: Relapsing-onset MS patients ( n = 19,318) were extracted from the Italian MS Registry. Risk factors for SPMS and for reaching irreversible Expanded Disability Status Scale (EDSS) 6.0, after SP transition, were estimated using multivariable Cox regression models. Results: SPMS identified by the DDA ( n = 2343, 12.1%) were older, more disa…

Oncologymedicine.medical_specialtyRelapsing-RemittingMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineDisease registryRecurrenceRisk Factorsbig dataInternal medicinemedicineHumansdata-driven algorithmMultiple sclerosi030212 general & internal medicinebig data; data-driven algorithm; disease registry; Multiple sclerosis; prognosis; secondary progressive; Disease Progression; Humans; Recurrence; Risk Factors; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-RemittingSecondary progressiveTransition (genetics)business.industryMultiple sclerosisMultiple Sclerosis Chronic Progressivemedicine.diseaseChronic ProgressiveNeurologybig data; data-driven algorithm; disease registry; Multiple sclerosis; prognosis; secondary progressiveDisease Progressiondisease registrysecondary progressiveSettore MED/26 - NeurologiaNeurology (clinical)prognosisbusinessprognosi030217 neurology & neurosurgery
researchProduct

IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci

2010

A recent meta-analysis identified seven single-nucleotide polymorphisms (SNPs) with suggestive evidence of association with multiple sclerosis (MS). We report an analysis of these polymorphisms in a replication study that includes 8,085 cases and 7,777 controls. A meta-analysis across the replication collections and a joint analysis with the discovery data set were performed. The possible functional consequences of the validated susceptibility loci were explored using RNA expression data. For all of the tested SNPs, the effect observed in the replication phase involved the same allele and the same direction of effect observed in the discovery phase. Three loci exceeded genome-wide significa…

Multiple SclerosisImmunologyGenome-wide association studyLocus (genetics)Single-nucleotide polymorphismBiologyPolymorphism Single NucleotideArticleInterleukin-12 Subunit p35Cell Line03 medical and health sciences0302 clinical medicineIL12AGeneticsmedicineHumansGenetic Predisposition to DiseaseAlleleGenetics (clinical)Cell Proliferation030304 developmental biologyGenetics0303 health sciencesTumor Suppressor ProteinsMultiple sclerosisCell cyclemedicine.disease3. Good healthCeliac DiseaseCase-Control StudiesImmunologyExpression quantitative trait lociLeukocytes MononuclearRGS Proteins030217 neurology & neurosurgeryGenes & Immunity
researchProduct

Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis

2022

Objective: This study was undertaken to describe and compare disease course and prognosis of early (ie, disease onset before age 11 years) and late (ie, disease onset after age 11 years) onset pediatric multiple sclerosis. Methods: Prospectively collected clinical information from Italian Multiple Sclerosis Register of 1993 pediatric multiple sclerosis patients, of whom 172 had early onset, was analyzed. Cox models adjusted for sex, baseline Expanded Disability Status Scale score, and disease-modifying treatments and stratified for diagnostic criteria adopted (Poser vs McDonald) were used to assess the risk of reaching irreversible Expanded Disability Status Scale scores of 3, 4, and 6, and…

MaleNatural History of Multiple SclerosisMultiple SclerosisNeurologyRecurrencePediatric Multiple SclerosisDisease ProgressionHumansDisabled PersonsSettore MED/26 - NeurologiaNeurology (clinical)ChildPrognosis
researchProduct

Individualisierte Hemikolektomie rechts bei Kolonkarzinomen

2013

Die chirurgische Behandlung von Karzinomen des rechten Kolons besteht unabhangig vom Zugang aus einer ablativen und einer rekonstruktiven Phase. Die ablative Phase gliedert sich in folgende Unterabschnitte: 1. Zugang; 2. Exploration; 3. Mobilisierung des rechten Kolon in CME-Technik (Complete Mesocolic Excision); 4. Durchtrennung der Gefase; 5. Durchtrennung von terminalem Ileum und Colon transversum. In der rekonstruktiven Phase wird eine Ileotransversoanastomose angelegt.

researchProduct

Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related d…

2022

Abstract Background Multiple sclerosis (MS) is characterized by phenotypical heterogeneity, partly resulting from demographic and environmental risk factors. Socio-economic factors and the characteristics of local MS facilities might also play a part. Methods This study included patients with a confirmed MS diagnosis enrolled in the Italian MS and Related Disorders Register in 2000–2021. Patients at first visit were classified as having a clinically isolated syndrome (CIS), relapsing–remitting (RR), primary progressive (PP), progressive-relapsing (PR), or secondary progressive MS (SP). Demographic and clinical characteristics were analyzed, with centers’ characteristics, geographic macro-ar…

Multiple SclerosisCenters’ characteristics; Italian Multiple Sclerosis Register; Multiple sclerosis phenotypes; Real-world dataSettore MED/42 - Igiene Generale e ApplicataItalian Multiple Sclerosis RegisterDermatologyGeneral MedicineMultiple Sclerosis Chronic ProgressiveSettore MED/26Settore SECS-S/04 - DemografiaCenters’ characteristicsMultiple sclerosis phenotypeReal-world dataSettore MED/01 - Statistica MedicaPsychiatry and Mental healthMultiple Sclerosis Relapsing-RemittingPhenotypeRecurrenceHumansFemaleSettore MED/26 - NeurologiaNeurology (clinical)Centers’ characteristicReferral and ConsultationMultiple sclerosis phenotypes
researchProduct

Prognostic indicators in pediatric clinically isolated syndrome

2017

To assess prognostic factors for a second clinical attack and a first disability worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of Multiple Sclerosis (MS) patients. Objective: To assess prognostic factors for a second clinical attack and a first disability-worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of multiple sclerosis (MS) patients. Methods: A cohort of 770 pCIS patients was followed up for at least 10 years. Cox proportional hazard models and Recursive Partitioning and Amalgamation (RECPAM) tree-regression were used to analyze data. Results: In pCIS, female sex and a multifocal onset were risk factors for a second clinical att…

RegistrieMaleMultiple SclerosisAdolescentAdolescent; Age of Onset; Child; Demyelinating Diseases; Female; Follow-Up Studies; Humans; Male; Multiple Sclerosis; Prognosis; Retrospective Studies; Risk Factors; Disease Progression; Registries; Neurology; Neurology (clinical)PrognosiONSET MULTIPLE-SCLEROSISCHILDHOODCHILDRENPARACLINICAL FEATURESDISABILITY PROGRESSIONNOFollow-Up StudieRisk FactorsRetrospective Studieprognostic indicatorsMultiple Sclerosipediatric multiple sclerosis prognosis indicatorsHumansRegistriesAge of OnsetChildOPTIC NEURITISRetrospective StudiesRisk FactorDemyelinating DiseaseNATURAL-HISTORYPrognosismultiple sclerosis clinically isolated syndrome prognostic indicatorsNeurologyTRANSVERSE MYELITISclinically isolated syndromeINTERFERON BETA-1BDisease ProgressionSettore MED/26 - NeurologiaFemaleNeurology (clinical)FOLLOW-UPDemyelinating DiseasesFollow-Up StudiesHuman
researchProduct